A new approach to targeting mucins via protein degradation shows promise against cancer.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Pedram, K. et al. Nat. Biotechnol. https://doi.org/10.1038/s41587-023-01840-6 (2023).
Brockhausen, I. & Melamed, J. Glyconj J. 38, 459–474 (2021).
Pearce, O. M. T. Glycobiology 28, 670–696 (2018).
Kufe, D. W. Oncogene 32, 1073–1081 (2013).
Beatson, R. et al. Nat. Immunol. 17, 1273–1281 (2016).
Piyush, T. et al. Cell Death Differ. 24, 1937–1947 (2017).
Paszek, M. J. et al. Nature 511, 319–325 (2014).
Taylor-Papadimitriou, J., Burchell, J. M., Graham, R. & Beatson, R. Biochem. Soc. Trans. 46, 659–668 (2018).
Békés, M., Langley, D. R. & Crews, C. M. Nat. Rev. Drug Discov. 21, 181–200 (2022).
Phillips, G. L. et al. Breast Cancer Res. Treat. 191, 303–317 (2022).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Beatson, R., Burchell, J.M. A mucin degrader for cancer therapy. Nat Biotechnol 42, 572–573 (2024). https://doi.org/10.1038/s41587-023-01984-5
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-023-01984-5